← Back to Search

Behavioral Therapy for Early Psychosis

N/A
Recruiting
Led By Stephanie Rolin, MD, MPH
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Summary

This trial is testing a program that helps people with early psychosis learn new ways to manage their emotions and actions to reduce violent behavior.

Who is the study for?
This trial is for young adults aged 16 to 30 who are receiving treatment for early psychosis at OnTrackNY clinics and can participate in research interviews. They must have a diagnosis within the schizophrenia spectrum, excluding affective psychoses, and be fluent in English.
What is being tested?
The study tests an adapted behavioral intervention designed to reduce violent behavior in individuals with early-stage nonaffective psychotic disorders such as schizophrenia.
What are the potential side effects?
Since this is a behavioral intervention rather than a medication, traditional side effects are not expected. However, participants may experience emotional or psychological discomfort during therapy sessions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Acceptability of Intervention Measure (AIM)
Mean Feasibility of Intervention Measure (FIM)
Number of EIS Participants in Attendance

Trial Design

1Treatment groups
Experimental Treatment
Group I: behavioral interventionExperimental Treatment1 Intervention
This will involve conducting a 12-week open pilot trial (up to n=16 dyads of EIS clinicians-EIS participants) to test the feasibility and acceptability of the adapted Psychological Interventions for Coping with Anger and Schizophrenia: a study of outcomes (PICASSO) intervention in the OnTrackNY setting.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for schizophrenia include behavioral therapies like Cognitive Behavioral Therapy (CBT) and antipsychotic medications. CBT helps modify thought patterns and improve coping strategies, which is crucial for managing symptoms such as delusions and hallucinations, reducing violent behavior, and enhancing social functioning. Antipsychotic medications work by altering neurotransmitter activity, particularly dopamine, to reduce psychotic symptoms. Combining these treatments offers a comprehensive approach, addressing both the biological and psychological aspects of schizophrenia.
Are Group Psychotherapeutic Treatments Effective for Patients with Schizophrenia? A Systematic Review and Meta-Analysis.

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,471 Previous Clinical Trials
2,536,334 Total Patients Enrolled
24 Trials studying Schizophrenia
3,310 Patients Enrolled for Schizophrenia
National Institute of Mental Health (NIMH)NIH
2,869 Previous Clinical Trials
2,777,520 Total Patients Enrolled
253 Trials studying Schizophrenia
89,908 Patients Enrolled for Schizophrenia
Stephanie Rolin, MD, MPHPrincipal InvestigatorColumbia University

Media Library

Adapted Behavioral Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05756855 — N/A
Schizophrenia Research Study Groups: behavioral intervention
Schizophrenia Clinical Trial 2023: Adapted Behavioral Intervention Highlights & Side Effects. Trial Name: NCT05756855 — N/A
Adapted Behavioral Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05756855 — N/A
~11 spots leftby Aug 2026